USP and Public Policy
Left
Refine Your Search
USP is please to provide a response to the Senate Committee on Health, Education, Labor, and Pensions (HELP) Request for Information on policies related to the Pandemic and All-Hazards Preparedness…
Learn More
USP appreciate the opportunity to respond to the request for information (RFI) from the Office of Science and Technology Policy (OSTP) on the National Biotechnology and Biomanufacturing Initiative.
Learn More
A resilient supply chain withstands acute disruptions so that safe, effective, and quality medicines can be supplied to patients around the globe, in adequate quantities, when they are needed. Poster…
Learn More
USP appreciates the opportunity to provide comments on ACIL’s “Guide to a Harmonized National Cannabis Laboratory Accreditation Program.
Learn More
USP supports leadership on the release of the discussion draft of the “Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act” (“PREVENT Pandemics Act."
Learn More
USP urged the California Assembly to consider highlighting the need for quality specifications as part of the regulatory framework for California Assembly Bill AB-45 and Senate Bill SB-235, “…
Learn More
USP greatly appreciate the opportunity to provide feedback on the Cannabis Administration and Opportunity Act (CAOA) Discussion Draft.
Learn More
USP appreciates the opportunity to comment on the State of New York’s proposed rulemaking, “Addition of Part 1005 to Title 10 NYCARR (Cannabinoid Hemp).”
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) Guidance for Industry, Control of Nitrosamine Impurities in Human Drugs.
Learn More
USP appreciates the opportunity to comment on FDA’s draft guidance Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.
Learn More